US IPO Weekly Recap: Snap files to raise $3 billion in a week with 4 IPOs
“The responsiveness and […] The company's File Number is listed as 0101025316.
Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support US IPO Weekly Recap: Snap files to raise $3 billion in a week with 4 IPOs
Get directions, reviews and information for Braeburn Pharmaceuticals in Princeton, NJ. Braeburn Biotechnology Plymouth Meeting, Pennsylvania 4,130 followers Braeburn is dedicated to delivering solutions for people living with the serious, often fatal consequences of OUD. But for now the only other drug that would potentially benefit from the new law, the monthly injectable opioid antagonist Vivitrol, is not subject to a patient cap. Princeton, New Jersey and Lund, Sweden — 14 November 2016 — Braeburn Pharmaceuticals and Camurus (STO:CAMX) are pleased to announce positive top-line results from a …
Experiencing withdrawals: Braeburn Pharmaceuticals officially withdraws $150 million IPO. The address is 47 Hulfish Street, Suite 441, Princeton, New Jersey, 08542, United States
Updated 1/17/2016: Sponsored Links. Princeton, New Jersey 08542-3713 .
Braeburn Pharmaceuticals, Inc. is a legal entity registered with LEI implemented by Global Legal Entity Identifier Foundation (GLEIF). BRAEBURN PHARMACEUTICALS, INC. NEW JERSEY FOREIGN FOR-PROFIT CORPORATION: WRITE REVIEW: Address: Registered Agent: Filing Date: January 07, 2013: File Number: 0101025316: Contact Us About The Company Profile For Braeburn Pharmaceuticals, Inc. EXHIBIT 10.5 . Braeburn Biotechnology Plymouth Meeting, Pennsylvania 4,130 followers Braeburn is dedicated to delivering solutions for people living with the serious, often fatal consequences of OUD. PRINCETON, NEW JERSEY and MONTREAL, QUEBEC--(Marketwired - June 13, 2017) - Braeburn Pharmaceuticals, Inc. ("Braeburn") and Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) has been accepted for review by Health Canada for PROBUPHINE® (buprenorphine … Menu & Reservations Make Reservations . Re: Braeburn Pharmaceuticals, Inc. Withdrawal of …
Braeburn focuses on the development and commercialization of medications for the treatment of central nervous system disorders.Braeburn's headquarters is located in Princeton, New Jersey, USA 08542. Princeton, New Jersey and Lund, Sweden — 2 May 2017 — Braeburn Pharmaceuticals and Camurus (NASDAQ STO: CAMX) today announced positive top-line results from a long-term Phase 3 trial supporting the safety and efficacy of CAM2038 (weekly and monthly buprenorphine depots) in patients with moderate-to-severe opioid use disorder. Braeburn Pharmaceuticals, Inc. is a New Jersey Foreign For-Profit Corporation filed on January 7, 2013.
The company's File Number is listed as 0101025316. It has raised 110.0M in 1 round. The Legal Entity Identifier (LEI) is 549300XTEF729UXNI136.
Braeburn Pharmaceuticals, Princeton, NJ, announces the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA).
United States Securities and Exchange Commission. View Related Trademarks
100 F Street, N.E. Division of Corporation Finance.
Feb 3, 2017.
One of Indivior’s main competitors, Braeburn Pharmaceuticals, has been fighting an uphill battle to get its own injectable buprenorphine/naloxone formulation through FDA approval.
Write Review: Upgrade: Claim: Braeburn Pharmaceuticals, Inc. is a New Jersey Foreign For-Profit Corporation filed on January 7, 2013. The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
This Employment Agreement (the “Agreement”) is effective as of October 1, 2016 (the “Effective Date”) between BRAEBURN PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and David McIntyre, a resident of the State of New Jersey, having an address located at 229 Brookstone Drive, Princeton, New Jersey (the “Executive”).
Experiencing withdrawals: Braeburn Pharmaceuticals officially withdraws $150 million IPO. Governing Law: New Jersey Date: 12/30/2016. Feb 22, 2017. This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of January 1 , 2016 (the “Effective Date”) between Braeburn Pharmaceuticals, Inc. (the “Employer” or “Company”), and Dr. Frank E. …
Reviews (609) 751-5375. Washington, DC 20549-3561. She currently also serves as the President and Chief Executive Officer of Braeburn Pharmaceuticals, Inc., or Braeburn, a …